Table 1.
Patient Characteristics1
| N | 62 |
|---|---|
| Age (years) | 47.4 ± 1.36 |
| Male (%) | 51 |
| BMI (kg/m2) | 36.8 ± 0.96 |
| BMI < 25 (%) | 1.6 |
| BMI 25 ≤ x < 30 (%) | 17.7 |
| BMI ≥30 (%) | 80.6 |
| NAS2 (0–8) | 4 (3–5.25) |
| Steatosis (0–3) | 2 (1–3) |
| Inflammation (0–3) | 1 (0–1) |
| Ballooning (0–2) | 1 (0–2) |
| Fibrosis2 (0–4) | 1 (0–1.25) |
| MG-H1 (pmol/mg protein) | 0.902 ± 0.050 |
| sRAGE (pg/ml) | 565.6 ± 19.5 |
| ALT (IU) | 66.35 ± 6.82 |
| ALP (IU) | 85.61 ± 3.76 |
| Bilirubin (μmol/L) | 11.79 ± 1.4 |
| Cholesterol (mmol/L) | 5.08 ± 0.19 |
| TAG (mmol/L) | 2.07 ± 0.23 |
| T2D (%) | 19.4 |
| HBP (%) | 35.5 |
1Mean ± SEM except as noted; 2median with 25% - 75% percentile. Abbreviations: BMI, body mass index; NAS, NAFLD activity score; MG-H1, methylglyoxal-hydroimidazolone 1; sRAGE, soluble receptor for advanced glycation endproducts; ALT, alanine aminotransferases; ALP, alkaline phosphatase; TAG, triacylglycerol; T2D, type 2 diabetes; HBP, high blood pressure.